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Abstract
Angiogenic, that is, newly formed, blood vessels play an important role in tumor growth and metastasis and are a
potential target for tumor treatment. In previous studies, the αvβ3 integrin, which is strongly expressed in angiogenic
vessels, has been used as a target for Arg-Gly-Asp (RGD)–functionalized nanoparticulate contrast agents for magnetic
resonance imaging–based visualization of angiogenesis. In the present study, the target-to-background ratio was
increased by diminishing the nonspecific contrast enhancement originating from contrast material present in the
blood pool. This was accomplished by the use of a so-called avidin chase, which allowed rapid clearance of non-
bound paramagnetic RGD-biotin-liposomes from the blood circulation. C57BL/6 mice, bearing a B16F10 mouse mela-
noma, received RGD-functionalized or untargeted biotin-liposomes, which was followed by avidin infusion or no
infusion. Precontrast, postcontrast, and postavidin T 1-weighted magnetic resonance images were acquired at 6.3 T.
Postcontrast images showed similar percentages of contrast-enhanced pixels in the tumors of mice that received
RGD-biotin-liposomes and biotin-liposomes. Post avidin infusion this percentage rapidly decreased to precontrast
levels for biotin-liposomes, whereas a significant amount of contrast-enhanced pixels remained present for RGD-
biotin-liposomes. These results showed that besides target-associated contrast agent, the circulating contrast agent
contributed significantly to the contrast enhancement as well. Ex vivo fluorescence microscopy confirmed association
of the RGD-biotin-liposomes to tumor endothelial cells bothwith and without avidin infusion, whereas biotin-liposomes
were predominantly found within the vessel lumen. The clearance methodology presented in this study successfully
enhanced the specificity of molecular magnetic resonance imaging and opens exciting possibilities for studying detec-
tion limits and targeting kinetics of site-directed contrast agents in vivo.
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Introduction
Angiogenesis, the formation of new blood vessels from preexisting
blood vessels, is an essential feature of tumor growth and metastasis
[1]. Consequently, numerous angiogenesis inhibitors have been de-
veloped during the last years as novel therapeutic agents for the treat-
ment of cancer [2]. Experimental and clinical studies have shown
that antiangiogenic therapy can indeed cause tumor growth arrest
or even tumor regression [3,4]. Within this research field, there is
a great need for advanced diagnostic tools that allow for the detection
of tumor angiogenesis in vivo because this would provide more and
earlier insight in treatment efficacy at the molecular level and in a
longitudinal fashion.
In the process of angiogenesis, activated endothelial cells up-
regulate the expression of the αvβ3 integrin, which binds to ex-
tracellular matrix components through their Arg-Gly-Asp (RGD)
sequence. Experimental studies have shown that the αvβ3 integrin
plays a pivotal role in angiogenesis because αvβ3 antagonists were
able to inhibit tumor angiogenesis [5]. Furthermore, a low expression
of the integrin is observed on resting endothelial cells, which makes
the αvβ3 integrin an excellent molecular marker for tumor angio-
genesis. Several studies have been performed, which used radio-
labeled [6] or fluorescently labeled [7] cyclic RGD peptides for the
in vivo detection of angiogenic blood vessels with either nuclear or
optical imaging techniques. These techniques display a high detec-
tion sensitivity for the imaging probes, but they reveal little anatomic
information. Therefore, RGD-conjugated gadolinium (Gd)–based
[8–13] or iron oxide–based [14] magnetic contrast agents were pro-
posed for the in vivo detection of tumor-associated αvβ3 expression
using magnetic resonance imaging (MRI) because this technique pro-
vides excellent contrast of opaque soft tissue. Most of these Gd-based
contrast agents were either based on liposomal [8,12,13] or on emul-
sion nanoparticles [10,11] that contain a large number of Gd3+ ions
per particle to deal with the inherently low sensitivity of MRI. The
average circulation half-life (t1/2) of such RGD-conjugated particles,
which is in the order of 2 to 8 hours [10,15,16], is significantly ele-
vated compared with the intrinsic blood half-life of the RGD-peptide
only (<10 minutes) [17]. A long blood half-life prolongs the time
window during which the contrast agent can accumulate at the tar-
geted site. However, long-circulating properties also allow pro-
longed time for extravasation, which, together with the blood pool
contrast agent, gives rise to unspecific contrast enhancement in the
T 1-weighted images because conventional T 1-weighted imaging
does not allow discrimination between circulating, extravasated and
target-associated contrast agent in the tumor. The contribution from
the circulating contrast agents can be eliminated by acquiring the
MR images when most of the contrast agent is cleared from the
blood, as demonstrated in a study by Sipkins et al. [8]. In this study,
MRI experiments were performed at 24 hours after injection of
LM609 antibody-conjugated paramagnetic polymerized liposomes
(t1/2 ∼ 8 hours) to enable target-specific imaging of tumor angio-
genesis. Moreover, signal from flowing blood can be suppressed,
which was shown to allow the visualization of contrast enhancement
in atherosclerotic plaques in the abdominal aorta already at 1 hour
after the injection of a long-circulating contrast agent (t1/2 ∼ 11 hours)
[18]. However, flow suppression in tumors is not that straightforward
owing to their complex and unstructured vasculature as well as the
relatively low blood flow rates in tumor blood vessels compared to that
in arteries [19,20]. Alternatively, in an experimental setting, a so-called
avidin chase can be applied to remove circulating contrast agent from
the blood. Avidin is a 66-kDa glycoprotein that displays a very short
intrinsic blood half-life and can bind four biotin molecules with high
affinity (K d < 10
−15 M) [21]. Sinitsyn et al. [22] were the first to show
that the biotin-avidin interaction can be used to rapidly clear long-
circulating biotinylated antibodies from the blood. This clearance
strategy has previously been used to increase the target-to-background
ratio of radiolabeled biotinylated monoclonal antibodies (mAbs) [23]
and liposomes [24] for nuclear imaging. The avidin chase has also been
applied to biotinylated dendrimer-based [25] and albumin-based [26]
MR contrast agents. Avidin-induced clearance of the latter agent al-
lowed studying vascular permeability and extravascular drainage in
tumors with MRI [26]. In previous studies, we showed that an avidin
chase can also be used to rapidly clear bimodal, that is, fluorescently
and gadolinium-labeled, biotin-liposomes from the blood pool [27]. In
the present study, we applied a similar avidin chase, or no chase, to
tumor-bearing mice that had been injected with either untargeted or
RGD-functionalized bimodal biotinylated liposomes. T 1-weighted
images were obtained precontrast, postcontrast, and postavidin infu-
sion to assess the relative contributions of circulating, target-associated,
and extravasated contrast agent to the signal enhancement. Fluores-
cence microscopy was performed to determine the spatial location of





(ethylene glycol))-2000] (PEG2000-DSPE), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N -[maleimide(poly(ethylene glycol))2000]
(Mal-PEG2000-DSPE), 1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N -[biotinyl(polyethylene glycol)2000] (biotin-PEG2000-DSPE)
and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N -(lissamine rho-
damine B sulfonyl) (rhodamine-PE) were obtained from Avanti Polar
Lipids (Albaster, AL). Gd-DTPA-bis(stearylamide) (Gd-DTPA-BSA)
was purchased from Gateway Chemical Technology (St. Louis, MO).
Liposomes were sized with a Lipofast Extruder (Avestin, Ottawa,
Ontario, Canada). Polycarbonate filters that were required for liposome
extrusion were obtained from Costar (Cambridge, MA). HEPES, PBS,
and paraformaldehyde were purchased from Sigma, Zwijndrecht, The
Netherlands, and bovine serum albumin (BSA) was obtained from Fluka,
Zwijndrecht, TheNetherlands. All other chemicals were of analytic grade
or of the best grade available.
Liposome Preparation
Paramagnetic liposomes were prepared by lipid film hydration of a
lipid mixture that typically contained 100 μmol of total lipid. For
biotinylated liposomes, Gd-DTPA-BSA, DSPC, cholesterol, Mal-
PEG2000-DSPE, PEG2000-DSPE, and biotin-PEG2000-DSPE were
used at a molar ratio of 0.75:1.1:1:0.075:0.045:0.03. Nonbiotinylated
control liposomes contained Gd-DTPA-BSA, DSPC, cholesterol,
Mal-PEG2000-DSPE, and PEG2000-DSPE at a molar ratio of
0.75:1.1:1:0.075:0.075. Lipid mixtures were dissolved in chloroform/
methanol 2:1 (v/v), and 0.2 mol% rhodamine-PE was added for fluo-
rescence microscopy. Subsequently, the solvent was removed by rotary
evaporation, followed by additional drying under nitrogen. The dry
lipid film was hydrated in 4 ml of HEPES-buffered saline (20 mM
HEPES and 135 mM NaCl, pH 6.7) at 65°C. The resulting large
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multilamellar vesicles were downsized to unilamellar liposomes by repeti-
tive (>10×) extrusion at 65°C through a stack of two 200-nm filters.
Coupling of RGD
Acetyl-protected cyclic RGD peptide (c(RGDf(-S -acetylthioacetyl)
K); Ansynth Service B.V., Roosendaal, The Netherlands) was activated
in a deacetylation solution (0.05 M HEPES, 0.05 M hydroxylamine,
0.03 mM EDTA, pH 7.0) at a 1:10 v/v ratio for 1 hour. Subsequently,
activated RGD peptide was added to the liposome suspensions at a
final concentration of 6 μg/μmol total lipid to allow covalent conju-
gation of the RGD peptide to Mal-PEG2000-DSPE by sulfhydryl-
maleimide coupling at 4°C overnight. Next, unbound RGD peptide
was removed by ultracentrifugation (1 hour at 60,000 rpm), and lipo-
somes were resuspended in HEPES buffered saline (20 mM HEPES
and 135 mM NaCl, pH 7.4) to a final concentration of approximately
50 mM total lipid. The final lipid concentration was determined by
a phosphate analysis according to Rouser et al. [28]. Dynamic light
scattering was performed using ZetasizerNano-S (Malvern Instruments,
Malvern, UK) to determine the hydrodynamic size of the liposomes, as
given by the intensity-weighted particle size distribution. Untargeted
biotin-liposomes and RGD-biotin-liposomes were measured to have a
mean diameter of 182 ± 8 nm and 190 ± 8 nm, respectively.
In Vitro Targeting
Target-specific association of RGD-liposomes to human umbilical
vein–derived endothelial cells (HUVECs) was previously demonstrated
bothwith confocal laser scanningmicroscopy andMRI [12]. In the pres-
ent study, the target-specificity of RGD-biotin-liposomes for HUVEC
was determined and compared to nonbiotinylated RGD-liposomes.
Human umbilical vein–derived endothelial cells were cultured at 37°C
in a humidified atmosphere and 5% CO2 in medium RPMI-1640 (Life
Technologies, Breda, The Netherlands), containing 20% human serum
(University Hospital Maastricht, The Netherlands), 2 mM glutamine
(Life Technologies), 100 U/ml penicillin, and 0.1 mg/ml streptomy-
cin (ICNBiomedicals, Aurora, OH). For each cell sample, approximately
1 × 106 HUVECs were grown in gelatin-coated culture flasks. Cells were
incubated with control-, RGD-, biotin- or RGD-biotin-liposomes for
3 hours at a final concentration of 1 mM total lipid in HUVEC culture
medium at 37°C in a humidified atmosphere that contained 5% CO2
in air. After incubation, cells were washed three times in warm HUVEC
medium (37°C). Fluorescence microscopy images were obtained, and
cells were washed once more in warm PBS (37°C). Next, HUVECs were
harvested using a mild trypsinization procedure, washed in PBS, and
resuspended in 4% paraformaldehyde (∼100 μl). Loosely packed cell
pellets were obtained by overnight settling in 250-μl polymerase chain
reaction tubes. Subsequently, apparent T 1 values of the pellets were mea-
sured at 6.3 T (20°C) using a fast T 1 inversion recovery sequence with
the following parameters: repetition time (TR) = 10 milliseconds, echo
time (TE) = 3 milliseconds, flip angle (α) = 15°, number of excitations
(NEX) = 2, matrix = 128 × 128, 32 segments, and 80 inversion times
ranging from 67.5 to 4807.5 milliseconds. Full recovery of the magneti-
zation between the different segments was allowed by using an overall
repetition time of 20 seconds. T 1 values were calculated as described
by Deichmann and Haase [29].
In Vivo Targeting
B16F10 melanoma cells were cultured in minimum essential me-
dium supplemented with Hank’s salts (Gibco, Invitrogen, Breda, The
Netherlands), 10% fetal calf serum, antibiotics, minimum essential
medium–vitamins, glutamine, nonessential amino acids, sodium pyru-
vate, and NaHCO3. At the onset of the experiment, cells were har-
vested, and a total of 28 C57BL/6 mice (Charles River, Maastricht,
The Netherlands) were inoculated subcutaneously with 1 × 105
B16F10 cells in 100μl of PBS on the right hind leg. All experiments were
approved by the animal ethical committee of Maastricht University.
Between 14 and 17 days after inoculation, the tumor size was
considered appropriate for MRI. Mice with a mean weight of 27 ±
4 g were initially anesthetized with 3% isoflurane in medical air
(0.4 L/min) that was supplied through a facemask. Anesthesia was
maintained using 0.8% to 1.6% isoflurane in medical air (0.4 L/min).
A catheter was placed in the tail vein, which allowed connecting to
two different tubings for subsequent injection of the contrast agent
and the avidin without prior mixture. Next, the avidin catheter was
connected to a syringe pump (Pico Plus; Harvard Apparatus, Holliston,
MA) that enabled infusion at a well-defined volume rate.
During the MR experiments, the mice were placed on a heating
plate to regulate their body temperature, whereas the respiratory sig-
nal was monitored using a pressure sensor connected to an electro-
cardiogram trigger unit (Rapid Biomedical, Rimpar, Germany) to
regulate the depth of the anesthesia. Each mouse received an intra-
venous bolus injection of RGD-biotin-liposomes (n = 14) or biotin-
liposomes (n = 14), at a dose of 5 μmol of total lipid. For seven mice
in each group, the infusion with avidin (0.2 mg/min; 2 mg total) was
started approximately 1.5 hours after contrast agent administration
(Figure 1), whereas the remaining mice (n = 7/group) were not in-
fused at all.
Figure 1. Time schedule of the in vivo MRI experiments.
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Magnetic resonance imaging was performed at 6.3 Ton a horizon-
tal bore magnet (Oxford Instruments Superconductivity, Eynsham,
Oxon, UK) interfaced to a Bruker imaging console (Bruker, Biospec,
Ettlingen, Germany), using a 3-cm birdcage send and receive coil
(Rapid Biomedical) for imaging. The time schedule of the com-
plete MRI experiment is shown in Figure 1. Multislice T 2-weighted
images were acquired to discriminate tumor tissue from the surround-
ing tissue using a fat-suppressed turbo spin echo sequence with TR =
4.2 seconds, TE = 25 milliseconds, turbo factor = 4, NEX = 8, matrix =
128 × 128, field of view (FOV) = 3 × 3 cm2, and a slice thickness of
1 mm. T 1-weighted images were acquired to demonstrate contrast
enhancement of tumor tissue using a fat-suppressed multislice spin
echo sequence with the following parameters: TR = 800 milliseconds,
TE = 8.8 milliseconds, NEX = 8, matrix = 128 × 128, and FOV = 3 ×
3 cm2. Slice positions of the T 1-weighted and T 2-weighted images
were identical. Three-dimensional FLASH images were obtained to
visualize the injection and clearance of the paramagnetic liposomes
from the large vessels using the following imaging parameters: TR =
10 milliseconds, TE = 3 milliseconds, α = 30°, matrix = 128 × 128 ×
64, and FOV = 3.2 × 3.2 × 4 cm3. All precontrast imaging parameters
and slice positions were exactly cloned for the corresponding post-
contrast imaging sequences.
Directly after the MR experiments, blood samples were collected
by orbital punction, mice were killed by cervical dislocation and
organ tissues, namely, liver, spleen, kidney, lung, and muscle, were
dissected and snap frozen in melting isopentane for fluorescence
microscopy and inductively coupled plasma (ICP) analysis of gado-
linium (Gd) content. Similarly, tumors were collected for fluores-
cence microscopy.
Magnetic Resonance Imaging Data Analysis
Small displacements in the animal position are difficult to avoid
during avidin infusion, which contributes to errors when analyzing
the contrast enhancement in the tumor tissue on a pixel-by-pixel
basis. Therefore, we used a method where the signal intensity of each
single pixel was compared to the average precontrast signal intensity
within the tumor tissue for each individual mouse. First, two regions
of interest (ROIs) were manually drawn in the T 2-weighted images,
which included the tumor tissue and a small area within the noise,
respectively. Next, the mean signal intensity within the tumor ROI
was calculated for the corresponding slices in the precontrast T 1-
weighted spin echo images (SItumorPre). The SD of the noise (SDnoise)
in the T 1-weighted spin echo images was determined by the mean
signal intensity within the noise ROI, divided by 1.25 [30]. Sub-
sequently, a threshold was set for each imaging slice that was defined
as SItumorPre + 5·SDnoise. Pixels within the tumor tissue were con-
sidered to be significantly enhanced when their signal intensity was
higher than the threshold set for that specific imaging slice. Con-
sequently, the precontrast image can also contain some pixels that
are classified as enhanced according to this definition.
The method described above was used to determine the fraction of
enhanced pixels within the total tumor for each individual mouse.
Next, the fraction of enhanced pixels in the precontrast images was
subtracted from the enhanced fractions in the corresponding post-
contrast T 1-weighted spin echo images, resulting in the real fraction
of contrast-enhanced pixels. From these values, the enhanced frac-
tions were calculated and averaged for each group (n = 7/group) at
every time point, resulting in a mean fraction ± SD. All data analyses
were performed in Matlab, using a custom-built routine.
Statistical Analysis
A repeated-measures analysis of variance, with a Greenhouse-
Geisser correction, was applied to detect time-dependent changes
in contrast enhancement. Post hoc pairwise comparisons between
the different time points, using a Bonferroni adjustment for multiple
comparisons, were performed for each individual group of mice.
Additional pairwise comparisons between RGD-biotin-liposomes
and biotin-liposomes at each individual time point were performed
using an unpaired Student’s t test. For these tests, non–avidin-infused
and avidin-infused mice were studied separately. Test statistics were
considered to be significant for P < .05. All analyses were performed
in SPSS 16.0.
Fluorescently Labeled Avidin
In the absence of an additional intervention, the avidin, as infused
during the in vivo MRI experiments, could not be detected by fluo-
rescence microscopy. Previous studies demonstrated that fluorescent
avidin (avidin-2-B4F) has similar blood clearance kinetics as avidin
[27]. Therefore, a total of three mice with a mean weight of 28 ± 2 g
were infused with fluorescently labeled avidin (2 mg; 0.2 mg/min),
starting approximately 1.5 hours after the intravenous administra-
tion of RGD-biotin-liposomes. Fluorescently labeled avidin (avidin-2-
B4F) was freshly prepared before the experiment. For convenience, this
was done by overnight incubation of avidin (Sigma) with biotin-4-
fluorescein (Sigma) at a 1:2 molar ratio at 4°C, as described previously
[27]. Approximately 1 hour after the onset of avidin infusion, mice were
killed, following exactly the same time schedule as used for the in vivo
MRI experiments. Tumors and organ tissues were excised and snap
frozen in melting isopentane for fluorescence microscopy.
Fluorescence Immunohistochemistry
Tumor tissue sections of 5 μm were cut at −20°C. Sections were
dried and stored at −80°C until the staining procedure was per-
formed. Before each staining procedure, tissue sections were thawed,
fixed for 5 minutes in cold acetone (−20°C), dried, and extensively
washed in PBS. Subsequently, an immunohistochemical staining for
endothelial cells was performed on all tumor tissue sections. First,
sections were incubated with 20% FBS/1% BSA/PBS for 15 minutes.
This solution was removed gently and immediately followed by incu-
bation with the primary mAb rat antimouse CD31 (BD Pharmingen,
Alphen aan de Rijn, The Netherlands), which was diluted to a 1:100
v/v ratio in 1% BSA in PBS. Tumor sections were incubated with the
primary antibody for 2 hours at room temperature followed by exten-
sive washing in PBS. Next, the sections were incubated for 1 hour with
the secondary antibody goat antirat Ig-G fluorescein isothiocyanate
(Zymed Laboratories, Invitrogen) at a 1:100 v/v ratio in 1% BSA
and 5% mouse serum (animal facilities, Maastricht University) in
PBS. Alternatively, tumor sections from mice that received avidin-2-
B4F were incubated with goat antirat IgG Alexa Fluor 350 (Molecular
Probes, Invitrogen) at a 1:200 v/v ratio under equivalent conditions.
Each tissue section was again extensively washed in PBS. In between
washing steps, sections that were incubated with the goat antirat Ig-G
fluorescein isothiocyanate secondary antibody were counterstained for
nuclei with 4′,6-diamidino-2-phenylindole (DAPI) (Molecular Probes,
Invitrogen) at a final concentration of 0.1 μg/ml in PBS. After the
staining procedure, tissue sections were covered with Mowiol mount-
ing medium, and fluorescence microscopy images of the stained
tissue sections were obtained using a fluorescence microscope (Zeiss,
Sliedrecht, The Netherlands). Shutter times were adjusted for the
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non–avidin-infused and the avidin-infused mice to allow visualization
of the liposomal rhodamine-lipid.
Biodistribution
The Gd content within the blood and the different organ tissues,
namely, liver, spleen, kidney, lung, and muscle, was determined with
ICP atomic emission spectrometry or mass spectrometry (ICP-AES/
ICP-MS). In short, organ tissues and blood samples were weighed,
placed in special tubes, and destructed in a mixture of perchloric and
nitric acid at 170°C until a clear solution was obtained. The Gd con-
tents within the solutions were determined using different dilutions
of a Gd stock solution for calibration.
Results
In Vitro Targeting
Human umbilical vein–derived endothelial cells were incubated
with nonbiotinylated or biotinylated paramagnetic liposomes, which
were either untargeted or functionalized with RGD-peptides. Fluores-
cence microscopy images clearly demonstrated specific association of
both the biotinylated and the nonbiotinylated RGD-functionalized
liposomes to HUVEC, whereas marginal association was observed
for both the untargeted nonbiotinylated (not shown) or untargeted
biotin-liposomes (Figure 2).
Quantitative MR measurements on the fixed cell pellets were in
good agreement with the fluorescence microscopy data, as relaxation
rates R1, that is, 1/T 1, were only found to be largely increased in
pellets of cells that were incubated with RGD-functionalized lipo-
somes (both biotinylated and nonbiotinylated). In contrast, R1 values
were only slightly increased for cells that were incubated with the
untargeted nonbiotinylated or biotin-liposomes in comparison to
untreated control cells (Figure 3). Importantly, no significant effects
of liposome biotinylation on target-specific or unspecific association
of the liposomes to HUVEC were observed (Figure 3).
In Vivo Targeting
T 2-weighted images were used to discriminate the tumor tissue
from surrounding muscle tissue, as the tumor tissue appeared hyper-
intense (Figure 4, A and H ). In the precontrast T 1-weighted images,
the tumors appeared essentially isointense with surrounding muscle,
with exception of some hypointense necrotic areas and hyperintense
regions in the tumor rim (Figure 4, B and I ). After injection of the
RGD-biotin-liposomes, the signal intensity in both tumor tissue and
large blood vessels, for example, around the spine, was increased
owing to the T 1 shortening effect of the paramagnetic liposomes
(Figure 4, C and J). The spatial distribution of significantly contrast-
enhanced pixels within the tumor was visualized by a color over-
lay on the original T 1-weighted image. As expected (Materials and
Methods section), some pre–contrast-enhanced pixels were already
present within the tumor because the signal intensity of these pixels
was calculated to be above the threshold that was used (Figure 4, E
and L). Without an avidin chase, most of the contrast enhance-
ment within the tumor and the blood vessels persisted until at least
2.5 hours after contrast injection (Figure 4D). In these mice, most
of the significantly contrast-enhanced pixels were found in the tumor
rim (Figure 4G). Tumor tissue was also shown to be contrast-enhanced
after the injection of untargeted biotin-liposomes (images not shown).
No differences between the untargeted and RGD-functionalized
biotin-liposomes were visually detected in the MR images.
The total fraction of contrast-enhanced pixels within the entire
tumor was quantified to compare the contrast enhancement after in-
jection with biotin-liposomes and RGD-biotin-liposomes. Approxi-
mately 30.8 ± 8.1% and 35.4 ± 6.7% of the tumor volume was
found to be significantly enhanced at 30 minutes after the intravenous
administration of the paramagnetic RGD-functionalized and un-
targeted biotin-liposomes, respectively (Figure 5A). Approximately
2.5 hours after injection of the RGD-biotin-liposomes, the enhanced
fraction was reduced to 24.4 ± 9.9%, whereas 29.3 ± 5.7% of the
Figure 2. Fluorescence microscopy images of HUVEC that were incubated for 3 hours with (A) biotin-liposomes (B-L), (B) RGD-liposomes
(RGD-L) or (C) RGD-biotin-liposomes (RGD-B-L), which contain rhodamine-PE (red). Original magnification, ×200.
Figure 3. Longitudinal relaxation rates R1 (1/T 1) of HUVEC cell pel-
lets after incubation with control liposomes (C-L), biotin-liposomes
(B-L), RGD-liposomes (RGD-L), or RGD-biotin-liposomes (RGD-B-
L). Untreated control cells (−) were added for comparison. Bars
represent mean R1 values ± SD (n = 2/group).
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tumor tissue was shown to be enhanced for the untargeted biotin-
liposomes. In these mice, no significant differences in the enhanced
fractions were observed between the two contrast agents at any time
point, which is in agreement with observations in a previous study [12].
In contrast to non–avidin-infused mice, the signal intensity in the
large blood vessels of avidin-infused mice returned toward precontrast
values within 1 hour after the onset of infusion, both in T 1-weighted
spin echo images (Figure 4K ) and T 1-weighted three-dimensional
FLASH images (data not shown). These results indicate avidin-induced
blood clearance of both biotin-liposomes and RGD-biotin-liposomes
[27]. In mice that had previously received RGD-biotin-liposomes,
the increased signal intensity within the tumor tissue was also visibly
reduced within 1 hour after the onset of avidin infusion (Figure 4K ).
Most pixels that remained significantly enhanced were located in the
tumor rim (Figure 4N ).
For avidin-infused mice, the fractions of significantly enhanced pixels
within the tumor were 26.7 ± 5.9% and 27.2 ± 8.2% at 30 min-
utes after injection of RGD-biotin-liposomes and untargeted biotin-
liposomes, respectively (Figure 5B). For the RGD-biotin-liposomes,
this fraction was significantly reduced to 10.3 ± 4.7% at 30 minutes
and 6.2 ± 3.9% at 1 hour after the onset of avidin infusion. In mice
that had been injected with biotin-liposomes, the percentage of en-
hanced pixels within the tumor was significantly decreased to 0.2 ±
2.4% and 1.4 ± 1.6% at the early and late time points after the onset
of avidin infusion. Importantly, at those two time points, the contrast-
enhanced fraction remaining after avidin infusion was significantly
higher for the RGD-biotin-liposomes compared to the biotin-liposomes.
No significant differences in tumor size were found between the differ-
ent groups (Figure 5, C and D), which excludes that the above differ-
ences in MRI contrast changes were caused by differences in tumor size.
Figure 4. T 2-weighted (A, H) and T 1-weighted spin echo pre- and postcontrast MR images (B–G, I–N) of tumor-bearing mice that received
an intravenous bolus of RGD-biotin-liposomes (RGD-B-L). The mouse in the upper panels (A–G) received no avidin. The mouse in the
lower panels (H–N) was infused with avidin starting directly after the acquisition of the image shown in J. Pixels within the tumor tissue
that were significantly enhanced are shown by a color overlay (E–G, L–N) on the corresponding T 1-weighted images in B–D and I–K,
respectively. Color bar represents percentage of signal increase relative to the threshold value.
1464 Improved MR Molecular Imaging of Angiogenesis van Tilborg et al. Neoplasia Vol. 10, No. 12, 2008
Fluorescence Immunohistochemistry
Fluorescence microscopy images demonstrated that the RGD-
biotin-liposomes colocalized with endothelial cells within the tumor
(Figure 6, A and B). Rhodamine fluorescence from these liposomes
was also found within the vessel lumen. Biotin-liposomes were also
detected within the lumen, whereas for this contrast agent, no endo-
thelial cell association was observed (Figure 6, C and D). After the
avidin chase, RGD-biotin-liposomes were found to remain co-
localized with the endothelial cells (Figure 6, E and F ). In this case,
the liposomal fluorescence was more intense and clustered compared
to mice that had received RGD-biotin-liposomes without avidin
infusion. Intensely fluorescent liposomal clusters were occasionally
also observed in the vessel lumen of avidin-infused mice that had
been injected with biotin-liposomes (Figure 6, G and H ).
Alternatively, three mice were infused with fluorescent avidin
(avidin-2-B4F) after the injection of RGD-biotin-liposomes to visu-
alize possible binding of avidin to target-associated contrast agents,
and its role in the formation of the aggregates that were described
above. Infusion with avidin-2-B4F clearly demonstrated that the
intense fluorescent liposomal clusters of RGD-biotin-liposomes
(Figure 7, A and B) colocalized both with avidin-2-B4F (Figure 7,
A and C ) and endothelial cells in the tumor (Figure 7, A and D).
Biodistribution
All mice were killed at approximately 170 minutes after the intra-
venous administration of the contrast agent. At this time point,
significant quantities of both the RGD-biotin-liposomes and the
biotin-liposomes were still present in the blood in case no avidin was
infused (Figure 8A). The concentration of RGD-biotin-liposomes
in the blood (60.9 ± 2.8 μg Gd/g tissue) was, however, slightly lower
than that of the biotin-liposomes (91.7 ± 24.7 μg Gd/g tissue). In
contrast, the amount of RGD-biotin-liposomes in the spleen (208.0 ±
7.1 μg Gd/g tissue) was higher compared to the biotin-liposomes
(131.0 ± 7.1 μg Gd/g tissue), whereas Gd levels in liver, kidney, and
lungs were comparable for the two liposomal preparations. In avidin-
infused mice, the blood pool concentration of both contrast agents was
decreased below 3.8 ± 0.7 μg Gd/g tissue, whereas the uptake in the
spleen, liver, and lungs was found to be strongly increased (Figure 8B).
In these avidin-infused mice, no differences in biodistribution were ob-
served between the RGD-biotin-liposomes and the biotin-liposomes.
No Gd uptake in skeletal muscle tissue was observed (data not shown).
Discussion
In the present study, we showed that an avidin chase can be used
to rapidly clear nonbound RGD-functionalized or untargeted biotin-
liposomes from the blood circulation, which facilitated early imaging
and increased the specificity of target-specific MRI of tumor angio-
genesis in vivo. Without avidin infusion, the RGD-functionalized
and untargeted biotin-liposomes caused similar levels of contrast en-
hancement in T 1-weighted MR images of B16F10 mouse melanoma,
which slowly decreased in time. In contrast, the percentage of contrast-
enhanced pixels in avidin-infused mice was rapidly reduced after the
onset of avidin infusion and resulted in a significantly higher contrast-
enhanced fraction for the RGD-biotin-liposomes compared with the
biotin-liposomes. The latter significant difference cannot be attributed
Figure 5. (A, B) Time dependence of the percentages of significantly contrast-enhanced pixels in T 1-weighted spin echo MR images of
tumors after subtraction of the pre–contrast-enhanced fraction. RGD-biotin-liposomes (RGD-B-L) or biotin-liposomes (B-L) were injected
at time 0. Subsequently, mice were left untreated (A) or avidin was infused between approximately 100 and 110 minutes after contrast
agent injection as indicated by the gray bar (B). Data points represent the mean fraction of enhanced pixels ± SD (n= 7/group). *P< .05
between the two contrast agents at the given time point. #P< .05 relative to the first postcontrast time point. (C, D) Mean tumor sizes ±
SD determined from the MR images for the different groups.
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to differences in Gd levels in the blood because ICP measurements
showed that the concentrations of Gd after the last imaging time point
were were very low in both cases, that is, 0.015 ± 0.007 and 0.024 ±
0.004 mM for the RGD-biotin-liposomes and the biotin-liposomes,
respectively. This is at least four times below the detection limits of
the current MRI scan procedure. Therefore, a significant fraction of
the contrast enhancement caused by RGD-biotin-liposomes in the tu-
mors of non–avidin-infused mice is assumed to originate from target-
associated contrast agent. The remaining contribution to the MRI
contrast enhancement most likely originated from contrast agent circu-
lating in the blood, which could potentially be used to determine the
total tumor blood volume. The above interpretation of the data was con-
firmed by fluorescence microscopy, as before the avidin chase RGD-
liposomes were found both in the vessel lumen and associated to the
endothelial cells in the tumors. The relatively small percentage of pixels
that remained enhanced within the tumors of avidin-infused mice that
had first received biotin-liposomes strongly suggests that little extravasa-
tion of these liposomes had occurred in the relatively short time span of
our study. This is supported by fluorescence microscopy images that
showed only little extravascular fluorescence. Several studies presented
Figure 6. Fluorescence microscopy images of tumor sections from mice that received RGD-biotin-liposomes (A, B, E, F) or biotin-
liposomes (C, D, G, H). Subsequently, mice were left untreated (A–D) or avidin was infused (E–H). Liposomal fluorescence from
rhodamine-PE is shown in the left panel. Sections were costained for endothelial cells using an antimouse CD31 antibody (green),
and for nuclei with DAPI (blue). Color overlays are shown in the right panel. Original magnification, ×400.
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in the literature showed that sterically stabilized liposomes indeed re-
quire considerable time to accumulate into tumors [31]. Interestingly,
the avidin chase can also be exploited for dynamic studies on the extent
of contrast agent extravasation in vivo. The actual rate and extent of
liposome extravasation depends both on the tumor type and microenvi-
ronment, as well as the size, dose, formulation, and blood half-life of
the liposomes [31,32]. In B16F10 melanoma tumor-bearing C57BL/6
mice, maximal accumulation of PEG-liposomes with a size of ∼100 nm
was observed around 16 hours after intravenous injection [33].
Calculated contrast-enhanced fractions of the tumor do not provide
absolute numbers on the volume fraction of angiogenic blood vessels
but only allows studying relative contributions of target-associated,
extravasated, or circulating contrast agent. This is because the measured
contrast-enhanced fractions are determined by multiple factors, includ-
ing imaging sequence parameters, signal-to-noise, and data analysis cri-
teria. Conventionally, contrast enhancement inMR images is quantified
by comparing the postcontrast signal intensity of each single pixel to its
precontrast signal intensity. However, pixel-by-pixel analysis could not
be applied in the present study because a careful analysis of the time-
course images revealed unacceptable displacements in the order of
≥2 pixels, when comparing images before and after the onset of avidin
infusion. Consequently, we needed to resort to an alternative method of
data analysis, in which the signal intensity was considered significantly
contrast-enhanced above a threshold value that was determined by
the average signal intensity in the tumor plus five times the standard
deviation of the noise. In this manner, an unbiased threshold was set
for each imaging slice. The disadvantage of this method is the occur-
rence of pre–contrast-enhanced pixels, which are excluded from the
final post–contrast-enhanced fraction, even if they are further enhanced
after contrast injection.
In the present study, the final contrast-enhanced fraction remain-
ing after avidin infusion was 6.2 ± 3.9% in mice that received RGD-
biotin-liposomes. We consider it likely that these values are relatively
low owing to the large extent of necrosis in the fast-growing B16F10
tumor model. A slower-growing tumor model might have resulted in a
larger fraction of target-associated contrast agent.
Figure 7. Fluorescence microscopy images of tumor sections from mice that had first been injected with RGD-biotin-liposomes, fol-
lowed by an avidin-2-B4F chase. The overlay (A) is composed of signal from rhodamine-PE in the liposomes (B), fluorescent avidin (C),
and endothelial cells, stained with an antimouse CD31 antibody (D). Original magnification, ×400.
Figure 8. Biodistribution of RGD-biotin-liposomes (RGD-B-L) and biotin-liposomes (B-L) approximately 3 hours after intravenous lipo-
somal administration, in mice that were subsequently left untreated (A) and in mice that were infused with avidin (B). Bars represent
mean Gd content per tissue ± SD (n = 2/group).
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Fluorescence microcopy images showed that avidin-2-B4F (Figure 7)
colocalized with a substantial fraction of the endothelial cell–associated
RGD-biotin-liposomes, which suggests limited internalization of this
contrast agent in vivo. Consequently, the infusion of avidin may have
dissociated a fraction of the membrane-bound RGD-biotin-liposomes
from the endothelial cells owing to the high binding affinity of avidin
to biotin. Moreover, avidin may also have bound to endothelial cell–
associated RGD-biotin-liposomes without dissociating the contrast
agent from these cells, which in turn could have recruited more
RGD-biotin-liposomes from the blood pool to the targeted site through
the biotin-avidin interaction. The latter effect indeed seemed to occur
because avidin-induced liposomal aggregates were observed in the tu-
mor, where they colocalized with the endothelial cells. Furthermore,
binding of avidin-2-B4F to the cell-associated RGD-biotin-liposomes
could have induced internalization of the RGD-biotin-liposome-
avidin-2-B4F complex as previously observed for biotinylated mAbs
[34] and dendrimers [35].
The onset of avidin infusion initiated an initial large drop in the per-
centage of contrast-enhanced pixels in the MR images in the RGD-
biotin-liposome group, which was further decreased in a gradual
manner. Possibly, this secondary decrease can be attributed to the grad-
ual dissociation of some target-associated RGD-biotin-liposomes. In
that case, some dissociation from the target may have also occurred
at the early time point after avidin infusion. Moreover, the measured
contrast enhancement could also suffer from partial quenching of the
T 1 shortening caused by limited water exchange with the inside of
the large target-associated liposomal aggregates that were formed by
the avidin-infusion and/or caused by the internalization of these aggre-
gates. Both partial dissociation and quenching of T 1 may lead to an
underestimation of the contribution of the target-associated contrast
agent to the observed contrast enhancement inT 1-weightedMR images.
Inductively coupled plasma analysis of the organ tissues showed a
higher uptake of the RGD-biotin-liposomes by the spleen compared
to the untargeted biotin-liposomes, whereas only little differences
were observed between the targeted and the untargeted liposomes
for the other organs. This is in agreement with previous studies
reported in the literature, which predominantly showed receptor-
dependent uptake of radiolabeled RGD by macrophages in the
spleen and liver when compared to non–integrin-binding controls
[17,36]. Radiolabeled long-circulating RGD-functionalized lipo-
somes also showed significantly increased accumulation in the spleen
at 24 hours after intravenous administration compared to control
liposomes both in rats [16] and in mice [15], whereas no significant
differences were observed in the liver. In those studies, the RGD-
liposomes displayed a blood half-life in the order of 2 to 8 hours,
which was increased by at least a factor 2 for control liposomes.
Blood half-lives of the untargeted and the RGD-functionalized
biotin-liposomes used in the present study were not determined. Al-
ternatively, the blood levels of Gd were measured at 170 minutes
after intravenous injection of the contrast agent. At this time point,
the blood levels of RGD-biotin-liposomes were lower than those of
biotin-liposomes. However, this difference was relatively small com-
pared to the RGD-induced decrease in liposomal blood levels de-
scribed in literature [15,16]. Differences in blood clearance kinetics
between the biotin-liposomes used in the present study and the
radiolabeled liposomes presented in literature could originate from
several differences in experimental design, including liposome dose,
liposome size, liposome composition, and the amount of RGD per
liposome [37].
In previous studies, massive avidin-induced accumulation of biotin-
liposomes was observed within the lungs at a spleen-to-lung ratio of
∼1:2 [27]. In contrast, in the present study, the Gd content in the
lungs on avidin infusion was relatively low, as the spleen-to-lung ratio
was measured to be ∼5.5:1. Most probably, this is caused by dif-
ferences in the time point at which the avidin infusion was started
because both the biotinylated liposomes and the avidin were adminis-
trated at the same dose and volume rate. In the previous study, the
infusion of avidin was started at 30 minutes after injection of the con-
trast agent, whereas it was started after 1.5 hours in the present study.
Consequently, the circulating levels of contrast agent were lower in the
present study, probably leading to smaller liposomal clusters that were
trapped by the lung capillaries to a smaller extent.
Over the last decades, liposomes were extensively applied as nano-
particulate drug carriers for cancer therapy to prevent drug degrada-
tion, inactivation, and adverse effects while increasing the amount of
drug delivered to the tumor [38]. As discussed above, RGD-biotin-
liposomes aggregate on the tumor endothelium of avidin-infused
mice. This aggregation could be exploited as an amplification method
to recruit large quantities of biotin-liposome–associated drugs to the
tumor endothelium. For this purpose, a third injection with the
drug-containing nanoparticle should be administered after the avidin
chase. These so-called three-step labeling approaches have already
been successfully applied to improve the target-to-background ratio
in nuclear imaging, by radiolabeling biotinylated mAbs only at the tar-
geted site after circulating mAbs were rapidly removed through an
avidin chase [39]. Importantly, in the present experimental setup, only
a relatively low dose of the nanoparticulate drug carrier would be re-
quired owing to the high binding affinity of biotin for avidin and the
abundance of biotin at the targeted site.
In conclusion, the clearance strategy presented in this study can
be used to investigate the relative contributions of target-associated,
extravasated, and circulating nonbound contrast agent to the MRI
contrast enhancement in the tumor tissue. This allows studying tumor
vascularization and tumor angiogenesis in a single MRI experiment.
Importantly, the presented strategy can be applied to remove the blood
pool component in the contrast-enhanced MR images at various sites
where flow suppression is not allowed or insufficient, which opens ex-
citing possibilities for studying detection limits and targeting kinetics
of target-specific MRI contrast agents in vivo.
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